Bevacizumab-Responsive Peptide (BRP) Aptamer Details

ID# 7611

Back to Search Results

Structure

Chemistry

Peptide

Target

Bevacizumab-treated Tumor

Sequence (3-char table code)

G A C U/T

NH2-LeuLeuAlaAspThrThrHisHisArgProTrpThr-COOH

Molecular Weight: 1583.81

Extinction Coefficient:

Binding Conditions / Buffer

Intracardiac injection of phage libraries. Amplified phages were partially purified by polyethyleneglycol(PEG) precipitation and resuspended in tris-buffered saline (TBS).

Binding Temp:

Refolding Protocol

If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference

Cao et al. "Phage display peptide probes for imaging early response to bevacizumab treatment." Amino Acids, 41(2011): 1103-1112.

Request a Quote Have your aptamer oligo synthesized by Aptagen.